Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 20.00% is 12% below its 5-year average of 22.74%, near the high end of its 5-year range (-377.44%–99.83%).
10.41% above its 12-month average of 18.11%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): -69.25%.
GROSS MARGIN
20.00%
GROSS MARGIN AVG TTM
18.11%
GROSS MARGIN AVG 3Y
19.98%
GROSS MARGIN AVG 5Y
22.74%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+10.41%
CURRENT VS 3Y AVG
+0.12%
CURRENT VS 5Y AVG
-12.05%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.44%
median of 713 covered companies
CURRENT VS SECTOR MEDIAN
-50.54%
vs the sector median at left
HCW Biologics Inc.
Market Cap
$563178.00
Gross Margin
20.00%
TTM Avg
18.11%
3Y Avg
19.98%
5Y Avg
22.74%
Market Cap
$375425.00
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
2.16%
5Y Avg
0.42%
Market Cap
$825495.00
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
4.91%
5Y Avg
3.27%
Market Cap
$873327.00
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$848489.00
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
16.67%
Market Cap
$1.03M
Gross Margin
-1.87%
TTM Avg
-0.94%
3Y Avg
-0.47%
5Y Avg
-0.37%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HCW Biologics Inc. (HCWB) | $563178.00 | 20.00% | 18.11% | 19.98% | 22.74% |
| CDT Equity Inc. (CDT)vs › | $670456.00 | 0.00% | 0.00% | 0.00% | 0.00% |
| Niki BioSolutions, Inc. (NIKI)vs › | $375425.00 | 0.00% | 0.00% | 2.16% | 0.42% |
| Ridgetech, Inc. (RDGT)vs › | $809925.00 | N/A | 3.40% | 12.49% | 15.69% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $825495.00 | 0.00% | 0.00% | 4.91% | 3.27% |
| Bone Biologics Corporation (BBLG)vs › | $873327.00 | 0.00% | 0.00% | 0.00% | 0.00% |
| Decoy Therapeutics Inc. (DCOY)vs › | $848489.00 | 0.00% | 0.00% | 0.00% | 16.67% |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | 0.00% | 0.00% | 0.00% | 0.00% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.03M | -1.87% | -0.94% | -0.47% | -0.37% |
| Psyence Biomedical Ltd. (PBM)vs › | $94810.00 | N/A | 0.00% | 0.00% | 0.00% |
Gross Margin
20.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -69.25% |
| 2026-03-31 | 99.83% |
| 2025-12-31 | 20.00% |
| 2025-09-30 | 20.00% |
| 2025-06-30 | 20.00% |
| 2025-03-31 | 20.00% |
| 2024-12-31 | 20.00% |
| 2024-09-30 | 20.00% |
| 2024-06-30 | 29.15% |
| 2024-03-31 | 54.56% |
| 2023-12-31 | -377.44% |
| 2023-09-30 | 20.49% |
| 2023-06-30 | 19.33% |
| 2023-03-31 | 29.92% |
| 2022-12-31 | 20.00% |
| 2022-09-30 | 20.00% |
| 2022-06-30 | 36.74% |
| 2022-03-31 | 57.40% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
